NVIDIA Biotechnology (Shanghai) Co., Ltd.

2025年4月4日，企业量化AI领域全球领导者SandboxAQ宣布Ray Dalio、Horizon Kinetics、BNP Paribas、Google和NVIDIA加入其E轮融资，该轮融资已筹集超过4.5亿美元。这些投资彰显了对SandboxAQ愿景及其大型定量模型（LQMs）变革能力的信心，这些模型正在重新定义企业如何利用AI应对复杂的科学和定量挑战。自2022年从Alphabet分拆以来，SandboxAQ已筹集超过9.5亿美元，以推动其在生物制药、化学、材料科学、网络安全和金融服务领域的定量AI平台发展。此前融资参见：加速AI下一波浪潮-大型定量模型开发｜SandboxAQ完成3亿美元融资这些新投资者加入了支持SandboxAQ发展的知名投资群体，包括Breyer Capital、Eric Schmidt、Alger、Paladin Capital、S32、TIME Ventures以及由T. Rowe Price Associates提供咨询的基金和账户。这种扩大的支持巩固了SandboxAQ在AI和量子技术领域的领导地位，推动了跨多个行业的创新。BNP Paribas企业与机构银行业务全球市场主管Olivier Osty表示：“AI和先进计算正在对金融服务产生重大影响，BNP Paribas Global Markets很自豪能站在这一趋势的前沿。我期待与SandboxAQ合作，在AI与量子技术的交叉领域探索创新解决方案。”Bridgewater Associates创始人Ray Dalio表示：“我看好SandboxAQ团队及其大型定量模型（LQMs）的方法，因为对两者都印象深刻。”关于SandboxAQSandboxAQ是一家B2B公司，提供人工智能和量子技术交叉的解决方案。该公司的大型定量模型（LQM）在生命科学、金融服务、导航和其他领域取得了重大进展。该公司从Alphabet中脱颖而出，成为一家独立的增长支持公司，由领先的投资者和战略合作伙伴提供资金。有关更多信息，请访问http://www.sandboxaq.com参考资料：https://www.sandboxaq.com/press/sandboxaq-closes-450m-series-e-round-with-expanded-investor-base--------- End ---------感兴趣的读者，可以添加小邦微信加入读者实名讨论微信群。添加时请主动注明姓名-企业-职位/岗位或姓名-学校-职务/研究方向。

With an initial investment of $10 million, Leidos, a technology services vendor in the healthcare, national security, energy and other sectors, said it hopes to accelerate the use of artificial intelligence for detecting and managing diseases in partnership with the University of Pittsburgh’s Computational Pathology and AI Center of Excellence. "These efforts will also focus on developing future healthcare specialists and expanding the care that’s available to underserved communities," Leidos CEO Tom Bell said in a statement on Friday. WHY IT MATTERS The new funding will help support the advancement of the university's state-of-the-art Digital Pathology Research Center to drive research in AI-driven diagnostics and digital pathology and ultimately get new tools into providers' hands. The initial focus of the five-year collaboration with CPACE will be developing AI-powered tools for quicker detection of diseases, such as heart disease and cancer, reducing diagnostic turnaround times and enabling earlier and more effective care management, Leidos said in its announcement. The multi-year collaboration includes plans for joint research projects that explore new imaging methods, advanced scanning technologies for analyzing tissue samples and improved techniques for more precise analyses of medical images, the company said. "Our investment is aimed at using the transformative power of artificial intelligence to speed detection, diagnosis and treatment of diseases that affect millions of people annually," said Bell. By merging academic excellence with technological innovation, the collaboration is poised to redefine the future of healthcare delivery and disease management, according to the partners. Their work will enhance the university's leadership in delivering advancements in diagnosis, disease management and healthcare delivery, according to Anantha Shekhar, senior vice chancellor for the health sciences and John and Gertrude Petersen Dean, UPitt's School of Medicine. It will also cultivate the next generation of healthcare and AI innovators through comprehensive educational programs, including industry-focused best practices, annual symposiums and hands-on internship opportunities where students will collaborate directly with the company's experts, Leidos said. THE LARGER TREND Many organizations are working with AI to advance disease detection from rare cancers and even to predict disease occurrences from routine imaging . Leidos said it is looking to expand its AI capabilities "beyond our traditional government customers" and teased "groundbreaking AI work across unconventional partnerships" on its website. The company has explored how domain-specific AI models could benefit healthcare organizations through an ongoing collaboration with Google and its Medical Pathways Language Model 2. Through that partnership, Leidos studied several use cases, including automated data analytics, document auto-generation and electronic health record search and summarization. "More accurate analysis of medical data can lead to faster diagnoses and better treatment plans," Srini Iyer, senior vice president and chief technology officer of Leidos Health & Civil Sector, told Healthcare IT News last year. UPitt has also long leveraged AI, from developing diagnostic support platforms that integrate with provider workflows to search medical record data to partnering with NVIDIA last year to accelerate medical research . ON THE RECORD "We want these tools to impact as many people as possible globally," said Hooman Rashidi, executive director of CPACE and associate dean of AI in medicine at the UPitt School of Medicine, in a statement. "Leidos can help get them into many more hands, ensuring that they are validated properly and get through the right regulatory frameworks." Andrea Fox is senior editor of Healthcare IT News. Email: afox@himss.org Healthcare IT News is a HIMSS Media publication.

到目前为止，基于AI的设计仅限于现有的数据集，达不到生物学领域要求的智能水平。基因组学在训练AI模型方面具有最大的潜力，例如，AlphaFold2模型。然而，在勘探活动挖掘生物多样性数据库时，公司往往未能确保各方之间的经济利益分享，导致了对利益分配不公平的日益不满，因此，使得生物技术公司缩减此类研究项目。近日，英国南安普顿综合医院的Ben Johnson在Nature biotechnology上发表AI biotechs launch bioprospecting expeditions with Indigenous groups, agree to share benefits，说明了AI生物技术公司开始与原住民和国家政府合作，开展生物勘探活动，以搜寻全球热点地区，收集新的DNA和蛋白质序列，用于开发具有商业价值的分子。伦敦的Basecamp Research公司通过与全球25个国家合作，建立了世界上最大的用于训练AI的生物多样性数据库。该公司专注于从极端环境收集物种的DNA和蛋白质序列，以开发具有商业潜力的新蛋白质。Basecamp在开展勘探活动前同意分享蛋白质收入，以避免传统商业生物勘探中的不公正和生物剽窃等行为。Basecamp的生物勘探活动不仅注重数据收集，还强调与当地社区的合作，在不违反伦理的前提下收集生物数据，并已与目标地达成了利润分享协议。2024年8月，Basecamp不仅与喀麦隆政府签署了一项利润分享合作协议，承诺将对当地生物DNA进行测序，并分享使用这些序列制造AI工具的利润，而且为喀麦隆的科学家提供研究资金，以促进当地生物多样性研究的发展。Basecamp的BaseGraph数据库已经比最大的公共数据库大10倍，包含DNA、蛋白质、环境和地理信息，从而帮助预测蛋白质的功能。Basecamp利用深度学习工具不仅预测大型复杂蛋白质的三维结构和相互作用，还能发现新蛋白质并优化它们以满足客户在化妆品、治疗、食品和生物修复方面的需求。此外，Basecamp还与NVIDIA合作开发用于药物发现的生成性AI平台，并与巴塞罗那分子生物学研究所合作开发了ZymCTRL工具，用于生成性蛋白质设计。Basecamp还注重合作交流，它与15家公司和高校合作，共同开发新的生物技术产品。Basecamp带动了其他生物技术公司开展生物勘探探险，同意分享利益。随着生物勘探的加速，全球正在形成新的协议，以确保其可持续性和道德性，避免生物剽窃行为。2024年5月，世界知识产权组织签署了一项新条约，以打击生物剽窃行为，并确保原住民和其他当地社区从这些发现中获得利润分成。综上，以Basecamp Research为代表的AI生物技术公司与土著群体和国家政府合作、在不违反伦理的前提下收集生物数据，开展生物勘探活动，并促进利益共享。（郭苗苗 摘译）